Relay Therapeutics, Inc. - Common Stock, $0.01 par value (RLAY)
CUSIP: 75943R102
Q2 2024 13F Holders as of 30 Jun 2024
- Type / Class
- Equity / Common Stock, $0.01 par value
- Shares outstanding
- 4,389,099
- Total 13F shares
- 126,697,163
- Share change
- -5,523,095
- Total reported value
- $826,050,230
- Put/Call ratio
- 1059%
- Price per share
- $6.52
- Number of holders
- 171
- Value change
- -$42,426,305
- Number of buys
- 91
- Number of sells
- 78
Quarterly Holders Quick Answers
What is CUSIP 75943R102?
CUSIP 75943R102 identifies RLAY - Relay Therapeutics, Inc. - Common Stock, $0.01 par value in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 75943R102:
Top shareholders of RLAY - Relay Therapeutics, Inc. - Common Stock, $0.01 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| SB INVESTMENT ADVISERS (UK) LTD |
13F
|
Company |
636%
|
27,904,963
|
$231,611,193 | — | 31 Mar 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
269%
|
11,815,669
|
$98,070,053 | — | 31 Mar 2024 | |
| BlackRock Finance, Inc. |
13F
|
Company |
223%
|
9,796,210
|
$81,308,545 | — | 31 Mar 2024 | |
| Casdin Capital, LLC |
13F
|
Company |
169%
|
7,423,574
|
$61,615,664 | — | 31 Mar 2024 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
157%
|
6,879,597
|
$57,101,000 | — | 31 Mar 2024 | |
| STATE STREET CORP |
13F
|
Company |
137%
|
6,020,988
|
$49,974,200 | — | 31 Mar 2024 | |
| Bellevue Group AG |
13F
|
Company |
135%
|
5,926,618
|
$49,190,929 | — | 31 Mar 2024 | |
| ArrowMark Colorado Holdings LLC |
13F
|
Company |
91%
|
4,005,170
|
$33,242,911 | — | 31 Mar 2024 | |
| Nextech Invest Ltd. |
13F
|
Company |
88%
|
3,846,409
|
$31,925,195 | — | 31 Mar 2024 | |
| BRAIDWELL LP |
13F
|
Company |
85%
|
3,743,999
|
$31,075,192 | — | 31 Mar 2024 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
85%
|
3,717,268
|
$30,853,325 | — | 31 Mar 2024 | |
| NORGES BANK |
13F
|
Company |
77%
|
3,392,625
|
$28,158,788 | — | 31 Mar 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
51%
|
2,216,793
|
$18,402,074 | — | 31 Mar 2024 | |
| Boxer Capital, LLC |
13F
|
Company |
41%
|
1,819,132
|
$15,098,796 | — | 31 Mar 2024 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
40%
|
1,763,148
|
$14,634,128 | — | 31 Mar 2024 | |
| JACOBS LEVY EQUITY MANAGEMENT, INC |
13F
|
Company |
38%
|
1,675,403
|
$13,905,845 | — | 31 Mar 2024 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
36%
|
1,600,814
|
$13,286,757 | — | 31 Mar 2024 | |
| Alphabet Inc. |
13F
|
Company |
36%
|
1,568,753
|
$13,020,649 | — | 31 Mar 2024 | |
| Finepoint Capital LP |
13F
|
Company |
34%
|
1,490,170
|
$12,368,411 | — | 31 Mar 2024 | |
| BAKER BROS. ADVISORS LP |
13F
|
Company |
26%
|
1,160,117
|
$9,628,971 | — | 31 Mar 2024 | |
| MORGAN STANLEY |
13F
|
Company |
26%
|
1,157,021
|
$9,603,275 | — | 31 Mar 2024 | |
| FMR LLC |
13F
|
Company |
25%
|
1,086,089
|
$9,014,539 | — | 31 Mar 2024 | |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
|
Company |
23%
|
999,639
|
$8,297,004 | — | 31 Mar 2024 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
22%
|
952,019
|
$7,901,758 | — | 31 Mar 2024 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
21%
|
912,157
|
$7,570,903 | — | 31 Mar 2024 | |
| MPM BioImpact LLC |
13F
|
Company |
19%
|
832,017
|
$6,905,741 | — | 31 Mar 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
19%
|
828,407
|
$6,875,779 | — | 31 Mar 2024 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
17%
|
763,200
|
$6,335,000 | — | 31 Mar 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
17%
|
741,703
|
$6,156,135 | — | 31 Mar 2024 | |
| Integral Health Asset Management, LLC |
13F
|
Company |
17%
|
725,000
|
$6,017,500 | — | 31 Mar 2024 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
13%
|
587,690
|
$4,877,827 | — | 31 Mar 2024 | |
| BESSEMER GROUP INC |
13F
|
Company |
13%
|
584,463
|
$4,851,000 | — | 31 Mar 2024 | |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC |
13F
|
Company |
13%
|
557,296
|
$4,625,558 | — | 31 Mar 2024 | |
| ALLIANCEBERNSTEIN L.P. |
13F
|
Company |
12%
|
538,603
|
$4,470,405 | — | 31 Mar 2024 | |
| S.c.a. Candriam |
13F
|
Individual |
12%
|
508,429
|
$4,219,961 | — | 31 Mar 2024 | |
| Rafferty Asset Management, LLC |
13F
|
Company |
11%
|
464,060
|
$3,851,698 | — | 31 Mar 2024 | |
| AMERIPRISE FINANCIAL INC |
13F
|
Company |
10%
|
450,172
|
$3,736,428 | — | 31 Mar 2024 | |
| Prosight Management, LP |
13F
|
Company |
10%
|
450,000
|
$3,735,000 | — | 31 Mar 2024 | |
| CITIGROUP INC |
13F
|
Company |
9.5%
|
414,977
|
$3,444,310 | — | 31 Mar 2024 | |
| DRIEHAUS CAPITAL MANAGEMENT LLC |
13F
|
Company |
9.1%
|
397,918
|
$3,302,719 | — | 31 Mar 2024 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
9%
|
394,300
|
$3,272,690 | — | 31 Mar 2024 | |
| PRUDENTIAL FINANCIAL INC |
13F
|
Company |
8.3%
|
362,450
|
$3,008,335 | — | 31 Mar 2024 | |
| TD ASSET MANAGEMENT INC |
13F
|
Company |
8.2%
|
358,656
|
$2,976,845 | — | 31 Mar 2024 | |
| BAILLIE GIFFORD & CO |
13F
|
Company |
8%
|
353,226
|
$2,931,776 | — | 31 Mar 2024 | |
| FEDERATED HERMES, INC. |
13F
|
Company |
7.7%
|
336,490
|
$2,792,867 | — | 31 Mar 2024 | |
| Bank of New York Mellon Corp |
13F
|
Company |
7%
|
306,448
|
$2,543,519 | — | 31 Mar 2024 | |
| ALGERT GLOBAL LLC |
13F
|
Company |
6.9%
|
301,935
|
$2,506,000 | — | 31 Mar 2024 | |
| HARBOURVEST PARTNERS LLC |
13F
|
Company |
6.8%
|
296,402
|
$2,460,137 | — | 31 Mar 2024 | |
| UBS Group AG |
13F
|
Company |
6.6%
|
287,926
|
$2,389,786 | — | 31 Mar 2024 | |
| Woodline Partners LP |
13F
|
Company |
6.2%
|
273,008
|
$2,265,966 | — | 31 Mar 2024 |
Institutional Holders of Relay Therapeutics, Inc. - Common Stock, $0.01 par value (RLAY) as of Q2 2024
As of 30 Jun 2024,
Relay Therapeutics, Inc. - Common Stock, $0.01 par value (RLAY) was held by
171 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
126,697,163 shares.
The largest 10 holders included
SB INVESTMENT ADVISERS (UK) LTD, VANGUARD GROUP INC, BlackRock Inc., Casdin Capital, LLC, Bellevue Group AG, PRICE T ROWE ASSOCIATES INC /MD/, STATE STREET CORP, JPMORGAN CHASE & CO, Nextech Invest Ltd., and NORGES BANK.
This page lists
172
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2024 vs Q1 2024 Across Filers
Q1 2024 holders
182
Q2 2024 holders
171
Holder diff
-11
| Investor | Q1 2024 Shares | Q2 2024 Shares | Share Diff | Share Chg % | Q1 2024 Value $ | Q2 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.